NOBLE Capital Markets Research
Advisory Approach
NOBLE Capital Markets is a research-driven investment bank with over 40 years of experience serving middle-market and emerging growth companies. Founded in 1984 and acquired by current CEO Nico P. Pronk in 1995, the firm operates with a distinctive thesis: successful capital raising and corporate advisory requires independent research, deep sector expertise, and transparent client relationships.
The firm's approach centers on being "research-driven"—they maintain an award-winning equity research team that produces independent, company-sponsored research. This research capability differentiates them from boutique investment banks that lack proprietary research coverage. Their sweet spot is publicly traded small-cap and microcap companies seeking growth capital through follow-on offerings, private placements, and ATM offerings, as well as private companies preparing for IPO or exploring strategic alternatives.
Sector Focus
NOBLE Capital Markets has developed particular strength in Healthcare & Life Sciences, led by Managing Partner Nathan Cali who has 18+ years of capital markets experience and previously served as a sell-side equity analyst for 9 years. The healthcare practice focuses on biotechnology, pharmaceuticals, and medical devices, with Nathan serving on the board of Precise Bio (tissue engineering) and previously as a board observer at Eledon Pharmaceuticals.
The firm also maintains significant expertise in Aerospace & Defense, evidenced by multiple follow-on offerings for Kratos Defense & Security Solutions totaling over $2.1 billion across 2024-2026. Their technology practice covers enterprise software, SaaS, and hardware, while their business services work spans media (Cumulus Media, Cox Media Group valuation engagements), broadcasting, and professional services.
Deal Track Record
NOBLE's transaction history demonstrates their capital markets specialization. Recent significant transactions include:
- Kratos Defense & Security Solutions: Co-manager on three follow-on offerings totaling over $2.1 billion (February 2026: $1.2B at $84.00/share; June 2025: $575M at $38.50/share; February 2024: $345M at $18.00/share)
- Eledon Pharmaceuticals: Co-placement agent on private placements totaling $234M (2024: $54M PIPE; 2023: $180M private placement)
- The GEO Group: Co-manager on $1.275B senior notes offering (April 2024) and sales agent on $300M ATM program (2023)
- Ocugen: Sole placement agent on $20M direct offering (August 2025)
- V2X: Co-manager on secondary offering (September 2024)
The firm has also provided valuation services to Cox Media Group and Cumulus Media, demonstrating fairness opinion and valuation advisory capabilities.
Process & Fee Structure
For capital markets transactions, NOBLE typically acts as co-manager, placement agent, or selling agent, working within syndicates led by larger investment banks. Their role involves leveraging their research coverage and institutional relationships to support deal execution. For M&A advisory engagements, Thomas Hill (Senior Managing Director, Head of M&A) leads buy-side and sell-side mandates.
The firm requires exclusivity on engagements and typically works with companies in the $20M-$500M enterprise value range. Their process emphasizes rigorous preparation, including research initiation, management presentation coaching, and structured roadshows through their Channelchek platform and annual NobleCon conference.
Fee structures vary by transaction type: for follow-on offerings and private placements, fees are typically a percentage of proceeds (industry standard 2-6% depending on deal size and complexity). For M&A advisory, success fees follow modified Lehman or industry-standard retainers, though specific fee data is not publicly disclosed.
Buyer Network
NOBLE maintains relationships with 2,000+ institutional investors through their Channelchek platform, a proprietary investment community that provides open access to equity research, tools, and events. This platform connects companies with retail and institutional investors, democratizing access to investment opportunities traditionally reserved for wirehouse clients.
The firm's institutional relationships span healthcare-focused funds, aerospace & defense specialists, technology investors, and special situations funds. Their annual NobleCon conference (21st edition in December 2025) brings together small- and micro-cap companies with qualified investors, creating a consistent deal flow pipeline.
Competitive Positioning
NOBLE differentiates through several unique capabilities:
- Research-Driven Approach: Award-winning equity research team produces independent coverage that drives institutional interest
- Channelchek Platform: Proprietary investor community with 40,000+ users providing direct access to retail and institutional capital
- Conference Franchise: NobleCon is a premier small-cap investing event, regularly featuring companies from healthcare, technology, industrials, and specialty finance
- Long-Term Client Relationships: 40-year operating history with many client relationships spanning decades
- Multidisciplinary Team: Professionals with backgrounds in equity research, investment banking, operations, and accounting
Not a Fit If
NOBLE typically declines engagements where:
- Companies are pre-revenue or lack a viable path to public markets (they focus on emerging growth, not early-stage venture deals)
- Transactions require pure asset sales or liquidation scenarios
- Businesses have significant undisclosed liabilities or pending litigation that cannot be resolved
- Founders want a limited process (the firm's value is in broad distribution through Channelchek and institutional relationships)
- Deal size is below $10M TEV (their minimum engagement threshold)
Team
Senior Leadership:
-
Nico P. Pronk — CEO, Head of Investment Banking. Owner since 1995. 25+ years experience in IPOs, secondary offerings, private placements, and M&A. Graduate of Netherlands Institute of Banking and Finance. Holds various FINRA licenses.
-
Nathan Cali — Managing Partner, Head of Healthcare Investment Banking. 18+ years capital markets experience. Previously sell-side equity analyst for 9 years. Board member of Precise Bio. Holds Series 7, 79, 86, 87 FINRA designations.
-
Thomas Hill — Senior Managing Director, Head of Mergers & Acquisitions. 25+ years investment banking, capital markets, and debt structuring experience. Previously Executive VP at Metropolitan Capital Bank & Trust, SVP at Palm Tree Securities and Banc of California. Closed dozens of middle-market transactions across aerospace & defense, consumer goods, healthcare, industrials, logistics, and telecommunications. M.S. from Johns Hopkins Carey School of Business. Holds Series 63 and 79.
-
Francisco Penafiel, ASA — Managing Director, Valuation and Advisory Services. 22+ years experience in portfolio management, investment banking, and business valuation. 7 years sell-side equity research experience covering enterprise software, business services, media, communications, and natural resources. Leads business development in Latin America. Accredited Senior Appraiser with American Society of Appraisers.
-
Joachim Bader — Managing Director, Head of Business Development. 22+ years combined experience in business development, M&A, and public accounting in the U.S. and Germany. Previously at CFGI (Carlyle and CVC Capital portfolio company) and heading M&A practice at a middle-market accounting advisory firm.
Geographic Coverage
Headquarters: Boca Raton, FL (150 East Palmetto Park Road, Suite 110)
Additional Offices:
- New York, NY (The Chrysler Building, 405 Lexington Ave)
- St. Louis, MO (393 N. Euclid)
- Westport, CT
The firm serves clients nationwide across the United States, with particular presence in Florida, New York, and the Midwest. Francisco Penafiel leads business development efforts in Latin America, providing international capabilities for Spanish-speaking clients.